CNC vs ZYME · P/E 8.4, rev $163.07B vs rev $76.3M
Centene Corp (CNC) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Centene Corp (CNC) is a healthcare plans company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
CNC currently screens at market cap $28.19B and trailing P/E 8.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the CNC and ZYME stock pages for the full models.
Not investment advice.